The health insurance industry: Perpetuating the opioid crisis through policies of cost-containment and profitability

Journal of Pain Research

Volumn 8, Issue , 2015, Pages 153-158

  Webster, Lynn R ^b  

^a Foundation for Ethics in Pain Care   (United States)

^b PRA HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; METHADONE; NARCOTIC ANALGESIC AGENT; OPIATE; OXYCODONE;

ADDICTION; COMORBIDITY; COST CONTROL; DRUG LEGISLATION; DRUG MARKETING; DRUG OVERDOSE; DRUG SURVEILLANCE PROGRAM; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MEDICAID; MEDICARE; NOTE; OPIATE ADDICTION; PAIN; PALLIATIVE THERAPY; PRESCRIPTION; PRIVATE HEALTH INSURANCE; PROFIT; REIMBURSEMENT; SLEEP DISORDER; SUBSTANCE ABUSE; UNITED STATES;

EID: 84930670258     PISSN: 11787090     EISSN: 11787090     Source Type: Journal    
DOI: 10.2147/JPR.S83368     Document Type: Note

References (77)

1. Centers for Disease Control and Prevention. Trends in drug-poisoning deaths involving opioid analgesics and heroin: United States, 1999–2012. Available from: http://www.cdc.gov/nchs/data/hestat/drug_poisoning/drug_poisoning.htm. Accessed January 31, 2015.
2. Centers for Disease Control and Prevention. Prescription drug overdose in the United States: fact sheet. Available from: http://www.cdc.gov/homeandrecreationalsafety/overdose/facts.html. Accessed January 31, 2015.
3. Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med. 2011;12 Suppl 2:S26–S35.
4. Meier B. Pain Killer: The Extraordinary and True Story of OxyContin. Emmaus, PA, USA: Rodale Press; 2003.
5. Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings. Rockville, MD, USA: Office of Applied Studies, NSDUH Series H-36, HHS Publication No SMA 09-4434; 2009.
6. Missouri Prescription Drug Monitoring Program NOW Coalition. Coalition News Release, November 24, 2014. Available from: http://mopdmpnow.org/media/coalition-news-releases/. Accessed February 3, 2015.
7. Fleming ML, Chandwani H, Barner JC, Weber SN, Okoro TT. Prescribers and pharmacists requests for prescription monitoring program (PMP) data: does PMP structure matter? J Pain Palliat Care Pharmacother. 2013;27:136–142.
8. Indiana Register. Medical licensing board of Indiana. Emergency rule. LSA document 13-495E. Available from: http://www.in.gov/legislative/iac/20131030-IR-844130495ERA.xml.pdf. Accessed February 25, 2015.
9. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6:107–112.
10. Darnall DB, Schatman ME. Urine drug screening: opioid risks preclude complete patient autonomy. Pain Med. 2014;15:2001–2002.
11. Goldberg DS, Rich BA. Pharmacovigilance and the plight of chronic pain patients: in pursuit of a realistic and responsible ethic of care. Indiana Health Law Rev. 2014;11:83–122.
12. Arnold RM, Han PK, Seltzer D. Opioid contracts in chronic nonmalignant pain management: objectives and uncertainties. Am J Med. 2006;119:292–296.
13. Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, Turner BJ. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010;152:712–720.
14. Schatman ME, Darnall BD. “Just saying no” to mandatory pain CME: how important is physician autonomy? Pain Med. 2013;14: 1821–1825.
15. Thomas D, Frascella J, Hall T, et al. Reflections on the role of opioids in the treatment of chronic pain: a shared solution for prescription opioid abuse and pain. J Intern Med. December 30, 2014. [Epub ahead of print.]
16. Cain J. Mandatory CME on opioid prescribing fails to address true causes of prescription drug abuse. Pain Med. 2013;14:1821–1822.
17. Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM. What we know, and don’t know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend. 2014;145:34–47.
18. Cheung CW, Qiu Q, Choi SW, Moore B, Goucke R, Irwin M. Chronic opioid therapy for chronic non-cancer pain: a review and comparison of treatment guidelines. Pain Physician. 2014;17:401–414.
19. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152:85–92.
20. Franklin GM, Mai J, Turner J, Sullivan M, Wickizer T, Fulton-Kehoe D. Bending the prescription opioid dosing and mortality curves: impact of the Washington State opioid dosing guideline. Am J Ind Med. 2012;55: 325–331.
21. Garg RK, Fulton-Kehoe D, Turner JA, et al. Changes in opioid prescribing for Washington workers’ compensation claimants after implementation of an opioid dosing guideline for chronic noncancer pain: 2004 to 2010. J Pain. 2013;14:1620–1628.
22. Anson P. Death rate from painkiller overdoses drops in Washington State. National Pain Report. January 28, 2013. Available from: http://nationalpainreport.com/death-rate-from-painkiller-overdoses-drops-in-washington-state-8818418.html. Accessed February 5, 2015.
23. Franklin GM, Fulton-Kehoe D, Turner JA, Sullivan MD, Wickizer TM. Changes in opioid prescribing for chronic pain in Washington State. J Am Board Fam Med. 2013;26:394–400.
24. Baum C, Hsu JP, Nelson RC. The impact of the addition of naloxone on the use and abuse of pentazocine. Public Health Rep. 1987;102: 426–429.
25. Cicero TJ, Inciardi JA, Muñoz A. Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002–2004. J Pain. 2005;6: 662–672.
26. Moorman-Li R, Motycka CA, Inge LD, Congdon JM, Hobson S, Pokropski B. A review of abuse-deterrent opioids for chronic nonmalignant pain. P T. 2012;37:412–418.
27. Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14:1122–1130.
28. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14:351–358.
29. Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22:1274–1282.
30. Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.Pharmacoepidemiol Drug Saf. 2014;23:1238–1246.
31. US Department of Health and Human Services/Food and Drug Administration. FDA approves abuse-deterrent labeling for reformulated OxyContin. April 16, 2013 http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm348252.htm. Accessed February 6, 2015.
32. Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Benedek IH, Comer SD. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012;126:206–215.
33. Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Shapiro DY, Comer SD. A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers. Addiction. 2013;108:1095–1106.
34. Lavonas EJ, Severtson SG, Martinez EM, et al. Abuse and diversion of buprenorphine sublingual tablets and film. J Subst Abuse Treat. 2014;47: 27–34.
35. Schatman ME, Darnall BD. A practical and ethical solution to the opioid scheduling conundrum. J Pain Res. 2014;7:1–3.
36. Schatman ME. The demise of multidisciplinary pain management clinics? Pract Pain Manag. 2006;6:30–41.
37. Schatman ME. The demise of the multidisciplinary chronic pain management clinic: bioethical perspectives on providing optimal treatment when ethical principles collide. In: Schatman ME, editor. Ethical Issues in Chronic Pain Management. New York, NY, USA: Informa Healthcare; 2007.
38. Schatman ME, Giordano J, Schatman ME. A crisis in pain care: an ethical analysis. Part 1. Facts, issues, and problems. Pain Physician. 2008;11:483–490.
39. Giordano J, Schatman ME. A crisis in chronic pain care: an ethical analysis. Part 3: Toward an integrative, multi-disciplinary pain medicine built around the needs of the patient. Pain Physician. 2008;11: 771–784.
40. Robinson JP, Leo R, Wallach J, McGough E, Schatman ME. Rehabilitative treatment for chronic pain. In: Stannard C, Kalso E, Ballantyne JC, editors. Evidence-Based Chronic Pain Management. Oxford, UK, USA: Blackwell Publishing; 2010;407–423.
41. Schatman ME. Interdisciplinary chronic pain management: perspectives on history, current status, and future viability. In: Ballantyne JC, Rathmell JP, Fishman SM, editors. Bonica’s Management of Pain, 4th edition. Philadelphia, PA, USA: Lippincott, Williams & Wilkins; 2010;1523–1532.
42. Schatman ME, Sullivan J. Whither suffering? The potential impact of tort reform on the emotional and existential healing of traumatically injured chronic pain patients. Psychol Inj Law. 2010;3:182–202.
43. Schatman ME. The role of the health insurance industry in perpetuating suboptimal pain management: ethical implications. Pain Med. 2011;12: 415–426.
44. Kitahara M, Kojima KK, Ohmura A. Efficacy of interdisciplinary treatment for chronic nonmalignant pain patients in Japan. Clin J Pain. 2006;22:647–655.
45. Turk DC, Swanson K. Efficacy and cost-effectiveness treatment for chronic pain: an analysis and evidence-based synthesis. In: Schatman ME, Campbell A, editors. Chronic Pain Management: Guidelines for Multidisciplinary Program Development. New York, NY, USA: Informa Healthcare; 2007;15–38.
46. Stanos S. Focused review of interdisciplinary pain rehabilitation programs for chronic pain management. Curr Pain Headache Rep. 2012;16: 147–152.
47. Gatchel RJ, McGeary DD, McGeary CA, Lippe B. Interdisciplinary chronic pain management: past, present, and future. Am Psychol. 2014;69:119–130.
48. Turk DC. Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin J Pain. 2002;18:355–365.
49. Gatchel RJ, Okifuji A. Evidence-based scientific data documenting the treatment and cost-effectiveness of comprehensive pain programs for chronic nonmalignant pain. J Pain. 2006;7:779–793.
50. Anooshian J, Streltzer J, Goebert D. Effectiveness of a psychiatric pain clinic. Psychosomatics. 1999;40:226–232.
51. Schatman ME. Interdisciplinary chronic pain management: international perspectives. Pain: Clinical Updates. 2012:20(7):1–5.
52. Poitras G. OxyContin, prescription opioid abuse and economic medicalization. Medicolegal Bioethics. 2012;2:31–43.
53. Robbins H, Gatchel RJ, Noe C, et al. A prospective one-year outcome study of interdisciplinary chronic pain management: compromising its efficacy by managed care policies. Anesth Analg. 2003;97:156–162.
54. Okifuji A. Interdisciplinary pain management with pain patients: evidence for its effectiveness. Sem Pain Med. 2003;1:110–119.
55. Bosy D, Etlin D, Corey D, Lee JW. An interdisciplinary pain rehabilitation programme: description and evaluation of outcomes. Physiother Can. 2010;62:316–326.
56. Murphy JL, Clark ME, Banou E. Opioid cessation and multidimensional outcomes after interdisciplinary chronic pain treatment. Clin J Pain. 2013;29:109–117.
57. Centers for Disease Control and Prevention: Vital signs: risk for overdose from methadone used for pain relief – United States, 1999–2010. MMWR Morb Mortal Wkly Rep. 2012;61:493–497.
58. Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain. 2014;15:321–337.
59. American Academy of Pain Medicine. The evidence against methadone as a “preferred” analgesic: a position statement from the American Academy of Pain Medicine; 2014. Available from: http://www.painmed.org/files/the-evidence-against-methadone-as-a-preferred-analgesic.pdf. Accessed February 19, 2015.
60. Brooks MJ. Mitigating the safety risks of drugs with a focus on opioids: are risk evaluation and mitigation strategies the answer? Mayo Clin Proc. 2014;89:1673–1684.
61. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84:593–601.
62. Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs. 2010;24:805–810.
63. Romach MK, Schoedel KA, Sellers EM. Update on tamper-resistant drug formulations. Drug Alcohol Depend. 2013;130:13–23.
64. Brushwood DB, Rich BA, Coleman JJ, Bolen J, Wong W. Legal liability perspectives on abuse-deterrent opioids in the treatment of chronic pain. J Pain Palliat Care Pharmacother. 2010;24:333–348.
65. Argoff CE, Stanos SP, Wieman MS. Validity testing of patient objections to acceptance of tamper-resistant opioid formulations. J Pain Res. 2013;6:367–373.
66. Cicero TJ, Kurtz SP, Surratt HL, et al. Multiple determinants of specific modes of prescription opioid diversion. J Drug Issues. 2011;41: 283–304.
67. Ben-Joseph R, Chen CC, De AP, Wade RL, Shah D. Consequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plans. J Med Econ. 2014;17:708–718.
68. Kirson NY, Shei A, White AG, et al. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States. Pain Med. 2014;15:1450–1454.
69. Butler SF, Fernandez KC, Chang A, et al. Measuring attractiveness for abuse of prescription opioids. Pain Med. 2010;11:67–80.
70. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367:187–189.
71. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300:2613–2620.
72. Katz NP, Birnbaum H, Brennan MJ, et al. Prescription opioid abuse: challenges and opportunities for payers. Am J Manag Care. 2013;19:295–302.
73. Brown ER, Lavarreda SA, Rice T, Kincheloe JR, Gatchell MS. The state of health insurance in California: findings from the 2003 California Health Interview Survey (August 2005). Available from: http://ucla-dev-web01.reliam.com/publications/Documents/PDF/The%20State%20of%20Health%20Insurance%20in%20California%20Findings%20from%20the%202003%20California%20Health%20Interview%20Survey.pdf. Accessed February 13, 2015.
74. Vietri J, Joshi AB, Barsdorf AI, Merdekian J. Prescription opioid abuse and tampering in the United States: results of a self-report survey. Pain Med. 2014;15:2064–2074.
75. Haas M, De Abreu Lourenco R. Pharmacological management of chronic lower back pain: a review of cost effectiveness. Pharmacoeconomics. January 22, 2015. [Epub ahead of print.]
76. Nayak RK, Pearson SD. The ethics of ‘fail first”: guidelines and practical scenarios for step therapy coverage policies. Health Aff (Millwood). 2014;33:1779–1785.
77. Irwin JA, Hopkins T, Conford P, et al. Sign up to support legislation in the New York state legislature that seeks to regulate “first fail” or “step therapy” drug policies imposed by health insurance companies. Available from:http://www.epilepsyuny.org/Documents/Step%20Therapy%20Advocacy%20Pkg.%2009%2009%2013.pdf. Accessed February 20, 2015.